LSR-1019

**LSR-1019** is a proprietary sublingual tablet formulation of **5-MeO-DMT** (5-methoxy-N,N-dimethyltryptamine), a fast-acting serotonergic psychedelic, developed by Lusaris Therapeutics for **treatment-resistant depression (TRD)** and potentially other neuropsychiatric disorders like migraine and cluster headache. It dissolves under the tongue within seconds for rapid absorption without water, enabling effects within minutes that last ~30 minutes, with potential therapeutic benefits via **neuroplasticity** persisting for weeks to a year based on preliminary evidence. As a **neuroplastogen**, it primarily acts as an agonist at serotonin **5-HT1A** receptors (with higher affinity than typical psychedelics) alongside activity at **5-HT2A** and other serotonin receptors, suppressing serotonin neuron firing and promoting brain plasticity without chronic dosing needs.[1][2][3][4][8][10]